1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6BD1044459E91D36F85256EBC006A4C9C
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/structuring-new-product-planning-and-strategic-alliance-teams?opendocument
18
19opendocument
20107.20.10.203
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Sales and Marketing New Product Development and Launch Managing Development Process Cross-Functional Teams Team Structure

Structuring New Product Planning and Strategic Alliance Teams

DB Image

ID: 4677


Features:

Graphics, Detailed Process Map


Pages/Slides: 9


Published: Pre-2013


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Study Overview

New product planning and strategic alliance teams are important for the overall health of the company. This document gives pharmaceutical companies a detailed breakdown of how to structure new product planning and strategic alliance teams. While organizational structures vary widely, particularly based on size of the company, they all aim to support overall corporate growth. Pharmaceutical companies will benefit from increased sales through more efficient new product planning and strategic alliance techniques. This nine-page report details how companies should mix structured and informal elements to enhance their strategic development dynamics.

Key Topics

  • Organizational Charts of the benchmark class companies
  • Design a New Product Planning and Strategic Alliance Structure to Support Corporate Growth


Sample Best Practices
  • Thoroughly distribute a mission statement to enhance the strategic alliance organization’s focus.
    *To define the scope of its strategic alliance activities, one company ensures thorough dissemination and awareness of its corporate business development mission statement. The statement also generally outlines the means to achieve that mission.
  • Define a clear new product-planning mission to guide department tasks.
    * One studied benchmark partner relies entirely upon developing licensing and co-promotions for its product pipeline.
  • Include strategic alliance goals in overall corporate objectives to align organization for business development.
    * Another studied company, for example, integrates two strategic alliance initiatives among its 20 company-wide, annual goals: successfully engage in at least one early-stage molecule in-licensing alliance, and successfully engage in at least one late-stage molecule in-licensing alliance.
Methodology
The insights and best practices showcased in this report are distilled from lessons learned in interviews with executives and specialists who have extensive experience in designing and managing new product planning and strategic alliance departments at a range of pharmaceutical companies. This document originated from a Best Practices, LLC consulting project.

Industries Profiled:
Pharmaceutical; Biotech; Health Care


Companies Profiled:
Eli Lilly; Pfizer; Amgen; Janssen


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.